NCT02468908已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim When Administered by Inhalation to Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Savara Inc.
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Number and severity of treatment-emergent Adverse Events (AEs) following single and multiple inhaled doses of molgramostim
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled, single ascending (SAD), and multiple ascending dose (MAD) study conducted at a single clinical site within the UK. Healthy male and female subjects (on non-child bearing potential) will be enrolled to investigate single inhaled doses of molgramostim at 3 dose levels (Part 1) and multiple inhaled doses at 2 dose levels (Part 2). The 2 doses in the multiple ascending dose regimens will be administered once daily (QD) for 6 consecutive days. The clinical indication for inhaled molgramostim is the treatment of respiratory diseases such as aPAP, bronchiectasis and cystic fibrosis. The Clinical trial will involve 42 healthy participants. The trial is expected to last approximately 4 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, adult, male or female, 18- 55 years of age, inclusive, at screening.
- •Life-long non smoker who has not used nicotine containing products.
- •Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
- •Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, spirometry, vital signs, or ECGs, as deemed by the PI.
- •Females must be of non-child bearing potential who must have undergone one of the following sterilization procedures at least 6 months prior to dosing in Part 1 or prior to the first dose in Part 2:
- •hysteroscopic sterilization;
- •bilateral tubal ligation or bilateral salpingectomy;
- •hysterectomy;
- •bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to dosing in Part 1 or prior to the first dose in Part 2, and FSH serum levels consistent with postmenopausal status as per PI's judgment.
- •A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non vasectomized male).
- •If male must agree not to donate sperm from dosing in Part 1 or from the first dose in Part 2, until 90 days following last dose.
- •Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.
排除标准
- •Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study.
- •History or presence of clinically significant medical condition(s) (including ongoing active infections) or psychiatric condition(s) or disease(s) in the opinion of the PI.
- •History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- •Abnormal spirometry test results, in the opinion of the PI.
- •History of severe or unexplained adverse reactions during aerosol delivery of any medicinal product.
- •History or presence of alcoholism or drug abuse within the past 2 years prior to screening.
- •History or presence of hypersensitivity or idiosyncratic reaction to molgramostim or to related compounds (i.e., Growgen®, Leucomax®, Leukine®, Topleucon™).
- •Clinically significant history or presence of ECG abnormalities such as second- or third degree atrioventricular block, evidence, or family history of prolonged QT syndrome.
- •Allergy to bandaids, adhesive dressing, or medical tape.
- •Positive urine drug at screening or check in.
- •Positive alcohol test at check-in.
- •Drink alcohol in excess of 21 units per week for males or 14 units per week for females, with one unit = 150 mL of wine or 360 mL of beer or 45 mL of 45% alcohol.
- •Positive urine cotinine at screening and check-in.
- •Positive results at screening for HIV, HBsAg, or HCV.
- •Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
- •Seated heart rate is lower than 45 bpm or higher than 99 bpm at screening.
- •QTcF interval is >430 msec (males) or >450 msec (females) at screening or deemed clinically abnormal by the PI.
- •Unable to refrain from or anticipates the use of:
- •Any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing in Part 1 or prior to the first dose in Part 2, and throughout the study. Hormone replacement therapy (HRT) is not permitted in this study and within 3 months prior to screening. During the study paracetamol (up to 2 g per 24 hours) may be administered at the discretion of the PI.
- •Any drugs known to be significant inducers of CYP enzymes and/or P gp, including St. John's Wort, for 28 days prior to dosing in Part 1 or prior to the first dose in Part 2, and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/PD interaction with study drug.
- •Have been on a diet incompatible with the on study diet, in the opinion of the PI, within the 28 days prior to the first dose of study drug, and throughout the study.
- •Haemoglobin or total WBC outside the normal range at screening.
- •Donation of blood or plasma within 90 days prior to dosing in Part 1 or prior to the first dose in Part
- •Donation of bone marrow within the last 6 months prior to dosing in Part 1 or prior to the first dose in Part
- •Participation in another clinical trial within 90 days prior to dosing in Part 1 or prior to the first dose in Part 2.
研究组 & 干预措施
Molgramostim nebuliser solution, inhaled
Experimental
Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
干预措施: Molgramostim (Drug)
Nebuliser solution, inhaled
Placebo Comparator
Inhaled nebuliser solution
干预措施: Placebo (Drug)
结局指标
主要结局
Number and severity of treatment-emergent Adverse Events (AEs) following single and multiple inhaled doses of molgramostim
时间窗: 1-6 days
次要结局
- PK parameters: Area under the plasma concentration time curve (AUC), Peak Peak Plasma concentration - Cmax, Time to reach maximum observed serum concentration - tmax(1-6 days)
- PK parameters: Apparent terminal elimination rate constant - k(el) and Apparent terminal elimination rate constant - t(1/2)(1-6 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-CHealthy VolunteerNCT01760187Aegerion Pharmaceuticals, Inc.72
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy VolunteersSafety IssuesNCT05004571Equilibre Biopharmaceuticals B.V.81
已完成
1 期
A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy VolunteersHealthy SubjectsNCT03879928Future Medicine50
Unknown
1 期
Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult SubjectsMigraineNCT04104399Xoc Pharmaceuticals32
Unknown
1 期
Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult SubjectsParkinson's DiseaseNCT04043338Xoc Pharmaceuticals56